S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
New CBOE “special perk” helps traders target income every weekend (Ad)
Elon Musk restores X account of conspiracy theorist Alex Jones
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
New CBOE “special perk” helps traders target income every weekend (Ad)
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
New CBOE “special perk” helps traders target income every weekend (Ad)
Elon Musk restores X account of conspiracy theorist Alex Jones
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
New CBOE “special perk” helps traders target income every weekend (Ad)
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
New CBOE “special perk” helps traders target income every weekend (Ad)
Elon Musk restores X account of conspiracy theorist Alex Jones
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
New CBOE “special perk” helps traders target income every weekend (Ad)
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
New CBOE “special perk” helps traders target income every weekend (Ad)
Elon Musk restores X account of conspiracy theorist Alex Jones
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
New CBOE “special perk” helps traders target income every weekend (Ad)
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way

Biogen (BIIB) Stock Price, News & Analysis

$239.29
+0.17 (+0.07%)
(As of 12/8/2023 ET)
Compare
Today's Range
$236.80
$240.81
50-Day Range
$222.59
$267.94
52-Week Range
$220.86
$319.76
Volume
987,954 shs
Average Volume
923,806 shs
Market Capitalization
$34.67 billion
P/E Ratio
23.79
Dividend Yield
N/A
Price Target
$321.26

Biogen MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
34.3% Upside
$321.26 Price Target
Short Interest
Healthy
1.83% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.39
Upright™ Environmental Score
News Sentiment
0.68mentions of Biogen in the last 14 days
Based on 23 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
5.55%
From $14.96 to $15.79 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.90 out of 5 stars

Medical Sector

42nd out of 933 stocks

Biological Products, Except Diagnostic Industry

5th out of 160 stocks


BIIB stock logo

About Biogen Stock (NASDAQ:BIIB)

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It also provides RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, immunology related diseases, neurovascular disorders, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. Biogen Inc. has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

BIIB Stock Price History

BIIB Stock News Headlines

Doing Your Holiday Shopping? These Stocks Might Make Great Gifts (BIIB)
No matter which holiday you're planning gifts for, Christmas, Hanukkah, or some other occasion, there may be one great gift idea you haven't thought of yet.
Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
GILD, BIIB, and KRTX: Biotech Buy, Hold, or Sell?
Raymond James Upgrades Biogen (BIIB)
Biogen (NASDAQ:BIIB) Upgraded by Raymond James to Outperform
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
The Latest Analyst Ratings for Biogen
Biogen: LAQEMBI's $10 Billion Potential
Barclays Reaffirms Their Hold Rating on Biogen (BIIB)
See More Headlines
Receive BIIB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biogen and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2023
Today
12/10/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/21/2024

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:BIIB
CUSIP
09062X10
Employees
8,725
Year Founded
1978

Price Target and Rating

Average Stock Price Target
$321.26
High Stock Price Target
$373.00
Low Stock Price Target
$239.00
Potential Upside/Downside
+34.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
23 Analysts

Profitability

Net Income
$3.05 billion
Pretax Margin
16.10%

Debt

Sales & Book Value

Annual Sales
$10.17 billion
Cash Flow
$21.54 per share
Book Value
$92.97 per share

Miscellaneous

Free Float
144,029,000
Market Cap
$34.67 billion
Optionable
Optionable
Beta
0.08

Social Links

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Mr. Christopher A. Viehbacher (Age 62)
    President, CEO & Director
    Comp: $487.94k
  • Mr. Michael R. McDonnell CPA (Age 59)
    Executive VP & CFO
    Comp: $2.12M
  • Ms. Nicole Murphy
    Head of Pharmaceutical Operations & Technology
  • Ms. Susan H. Alexander Esq.Ms. Susan H. Alexander Esq. (Age 66)
    Executive VP & Chief Legal Officer
    Comp: $2.2M
  • Dr. Ginger Gregory (Age 55)
    Executive VP & Chief Human Resources Officer
    Comp: $1.59M
  • Ms. Robin C. Kramer (Age 57)
    Senior VP & Chief Accounting Officer
  • Mr. Charles E. Triano
    Senior VP & Head of Investor Relations
  • Ms. Natacha Gassenbach
    Chief Communication Officer & Head of Corporate Affairs
  • Mr. Adam Keeney Ph.D.
    Executive VP & Head of Corporate Development
  • Ms. Alisha A. Alaimo
    President & Head of North America

Should I Buy Biogen Stock? BIIB Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Biogen was last updated on Tuesday, November 28, 2023 at 10:15 AM.

Pros

Here are some ways that investors could benefit from investing in Biogen Inc.:

  • Biogen Inc. is a leading company in discovering, developing, manufacturing, and delivering therapies for treating neurological and neurodegenerative diseases.
  • Biogen Inc. has a strong track record of innovation and has been at the forefront of developing groundbreaking treatments for various diseases.
  • Recent developments in Biogen Inc.'s pipeline show promising potential for new therapies that could address unmet medical needs.
  • Biogen Inc. has established strategic partnerships with other prominent companies in the biotech industry, such as Ionis Pharmaceuticals, Inc., Eisai Co., Ltd., Sangamo Therapeutics, Inc., and Sage Therapeutics, Inc.
  • Investors may find the current stock price of Biogen Inc. attractive, considering the company's growth prospects and recent developments.

Cons

Investors should be bearish about investing in Biogen Inc. for these reasons:

  • Biogen Inc. operates in a highly competitive industry, and there is always a risk of new entrants or existing competitors developing superior therapies.
  • The success of Biogen Inc. heavily relies on the approval and commercial success of its pipeline products, which may face regulatory hurdles or market challenges.
  • Investing in biotech companies like Biogen Inc. involves inherent risks associated with clinical trials, regulatory approvals, and the uncertain nature of drug development.
  • Changes in healthcare policies or reimbursement rates could impact the pricing and profitability of Biogen Inc.'s therapies.
  • Investors should carefully consider the potential risks and uncertainties associated with investing in Biogen Inc. before making any investment decisions.














BIIB Stock Analysis - Frequently Asked Questions

Should I buy or sell Biogen stock right now?

23 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Biogen in the last year. There are currently 4 hold ratings and 19 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" BIIB shares.
View BIIB analyst ratings
or view top-rated stocks.

What is Biogen's stock price target for 2024?

23 equities research analysts have issued twelve-month price targets for Biogen's stock. Their BIIB share price targets range from $239.00 to $373.00. On average, they expect the company's share price to reach $321.26 in the next twelve months. This suggests a possible upside of 34.3% from the stock's current price.
View analysts price targets for BIIB
or view top-rated stocks among Wall Street analysts.

How have BIIB shares performed in 2023?

Biogen's stock was trading at $276.92 at the beginning of the year. Since then, BIIB shares have decreased by 13.6% and is now trading at $239.29.
View the best growth stocks for 2023 here
.

When is Biogen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 21st 2024.
View our BIIB earnings forecast
.

How were Biogen's earnings last quarter?

Biogen Inc. (NASDAQ:BIIB) announced its quarterly earnings results on Wednesday, November, 8th. The biotechnology company reported $4.36 earnings per share for the quarter, beating analysts' consensus estimates of $3.99 by $0.37. The biotechnology company had revenue of $2.53 billion for the quarter, compared to analysts' expectations of $2.40 billion. Biogen had a net margin of 14.63% and a trailing twelve-month return on equity of 16.40%. The firm's revenue was up .9% on a year-over-year basis. During the same period last year, the company posted $4.77 earnings per share.
Read the conference call transcript
.

What guidance has Biogen issued on next quarter's earnings?

Biogen updated its FY23 earnings guidance on Wednesday, November, 8th. The company provided EPS guidance of $14.50-15.00 for the period, compared to the consensus EPS estimate of $15.29.

What is Michel Vounatsos' approval rating as Biogen's CEO?

394 employees have rated Biogen Chief Executive Officer Michel Vounatsos on Glassdoor.com. Michel Vounatsos has an approval rating of 86% among the company's employees. 72.0% of employees surveyed would recommend working at Biogen to a friend.

What other stocks do shareholders of Biogen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biogen investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Amgen (AMGN), Walt Disney (DIS), Intel (INTC), Micron Technology (MU) and Boeing (BA).

Who are Biogen's major shareholders?

Biogen's stock is owned by many different retail and institutional investors. Top institutional shareholders include Primecap Management Co. CA (11.05%), Wellington Management Group LLP (3.71%), Clearbridge Investments LLC (1.26%), Northern Trust Corp (1.13%), Morgan Stanley (1.03%) and Bank of New York Mellon Corp (0.99%). Insiders that own company stock include Alfred Sandrock, Brian S Posner, Ginger Gregory, Priya Singhal and Susan H Alexander.
View institutional ownership trends
.

How do I buy shares of Biogen?

Shares of BIIB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

Does Biogen have any subsidiaries?
The following companies are subsidiares of Biogen: BIIB Colombia S.A.S., Biogen (Argentina) SRL, Biogen (Bermuda) Technologies Ltd., Biogen (Czech Republic) s.r.o., Biogen (Denmark) A/S, Biogen (RTP) Realty LLC, Biogen Australia PTY Ltd, Biogen Austria GmbH, Biogen B.V., Biogen Belgium N.V./S.A., Biogen Biotechnology (Shanghai) Co. Ltd, Biogen Brasil Produtos Farmaceuticos LTDA, Biogen Canada Inc., Biogen Chesapeake LLC, Biogen Chile Spa, Biogen Digital Health Inc., Biogen Estonia OU, Biogen Finland OY, Biogen Foundation Inc., Biogen France S.A.S., Biogen GmbH, Biogen Holding I LLC, Biogen Holding II LLC, Biogen Hong Kong Limited, Biogen Hungary KFT, Biogen Idec (Ireland) Ltd., Biogen Idec Biotech India Pvt. Ltd., Biogen Idec Limited, Biogen Idec Research Ltd., Biogen Idec Uruguay SA, Biogen International GmbH, Biogen International Holding Limited, Biogen International Neuroscience GmbH, Biogen Italia S.R.L., Biogen Japan Ltd., Biogen Korea LLC, Biogen Latvia SIA, Biogen Lithuania UAB, Biogen Luxembourg Holding S.a.r.l., Biogen MA Inc., Biogen Management Services GmbH, Biogen Manufacturing Holding LLC, Biogen Mexico S. DE R.L. DE C.V., Biogen NZ Biopharma Ltd., Biogen Netherlands B.V., Biogen New Ventures Inc., Biogen Norway AS, Biogen Pharma d.o.o., Biogen Pharma farmacevtska in biotehnoloska druzba d.o.o., Biogen Poland Sp. z.o.o., Biogen Portugal Sociedade Farmaceutica Unipessoal Lda., Biogen Realty Corporation, Biogen Realty Limited Partnership, Biogen SRO Inc., Biogen Slovakia s.r.o., Biogen Spain S.L., Biogen Sweden AB, Biogen Swiss Investments GmbH, Biogen Swiss Manufacturing GmbH, Biogen Switzerland AG, Biogen Switzerland Holdings GmbH, Biogen Taiwan Limited, Biogen Therapeutics Inc., Biogen Turkey Ilac Ticaret Limited Sirketi, Biogen U.S. Corporation, Biogen U.S. Limited Partnership, Biogen U.S. Pacific LLC, Biogen U.S. West Corporation, Conforma Therapeutics, Conforma Therapeutics Corporation, Convergence Pharmaceuticals, Convergence Pharmaceuticals Holdings Ltd., Convergence Pharmaceuticals Limited, Eidetica Biopharma GmbH, Fumapharm, IDEC Pharmaceuticals Corporation, NightstaRx Limited, Nightstar Europa Limited, Nightstar Inc., Nightstar Therapeutics Limited, Nightstar Therapeutics plc, Old Convergence Pharmaceuticals Limited, Panima Pharmaceuticals AG, Silver Acquisition Co. Ltd., Stromedix Inc., Stromedix Inc., Syntonix Pharmaceuticals Inc., TYSABRI, and Tungsten Bidco Limited.
Read More
This page (NASDAQ:BIIB) was last updated on 12/10/2023 by MarketBeat.com Staff

My Account -